Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Atrandi Biosciences, a Lithuanian biotech company, has successfully raised $25 million in Series A financing, led by Lux Capital. The funding will support the expansion of their innovative single-cell analysis technology, which has garnered attention from leading scientists in the field. Atrandi is also planning to establish a presence in Boston as part of its growth strategy. CEO Juozas Nainys highlighted the burgeoning biotech scene in Lithuania, likening it to the early days of Silicon Valley.
🚨 We're thrilled to lead Atrandi Biosciences $25M Series A 🚨 Their groundbreaking single-cell analysis tech from Lithuania is already winning over top scientists in the field, enabling new types of cellular analysis at scale🧬 Read more: https://t.co/KR8eNNngv5
Our Seedcamp Nation is having a great run in Q1 2025! 🇬🇧 GenAI pioneer @synthesiaIO secured a $180M Series D at a $2.1B valuation to further develop its AI video platform, now used by over 1M people 🇬🇧 @LindusHealth closed a $55M Series B to speed up clinical trials https://t.co/d2zFlfKM57
Lithuanian biotech company secures $25M to expand single-cell research in the US https://t.co/1cXftHAlN0 via @ArcticStartup @PracticaCapital @tommyoehl @Lux_Capital @AtrandiBio #balticmade #Lithuania #funding #Biotechnology #deeptech #lifesciences #startups #Trending
